PL3570940T3 - Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x - Google Patents
Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu xInfo
- Publication number
- PL3570940T3 PL3570940T3 PL18741607.8T PL18741607T PL3570940T3 PL 3570940 T3 PL3570940 T3 PL 3570940T3 PL 18741607 T PL18741607 T PL 18741607T PL 3570940 T3 PL3570940 T3 PL 3570940T3
- Authority
- PL
- Poland
- Prior art keywords
- pridopidine
- fragile
- syndrome
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448595P | 2017-01-20 | 2017-01-20 | |
| PCT/US2018/014169 WO2018136600A1 (en) | 2017-01-20 | 2018-01-18 | Use of pridopidine for the treatment of fragile x syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3570940T3 true PL3570940T3 (pl) | 2024-06-17 |
Family
ID=62908348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18741607.8T PL3570940T3 (pl) | 2017-01-20 | 2018-01-18 | Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11234973B2 (pl) |
| EP (1) | EP3570940B1 (pl) |
| JP (1) | JP7114604B2 (pl) |
| CN (1) | CN110505902B (pl) |
| AU (1) | AU2018210145B2 (pl) |
| BR (1) | BR112019015000A2 (pl) |
| CA (1) | CA3050700C (pl) |
| DK (1) | DK3570940T3 (pl) |
| ES (1) | ES2972205T3 (pl) |
| HU (1) | HUE068300T2 (pl) |
| IL (1) | IL268125B2 (pl) |
| PL (1) | PL3570940T3 (pl) |
| WO (1) | WO2018136600A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| EP4516356A3 (en) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3678664A1 (en) | 2017-09-08 | 2020-07-15 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| WO2020161707A1 (en) | 2019-02-04 | 2020-08-13 | Prilenia Neurotherapeutics Ltd. | Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism |
| WO2021141426A1 (ko) * | 2020-01-08 | 2021-07-15 | 건국대학교 글로컬산학협력단 | 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6472736A (en) | 1987-09-14 | 1989-03-17 | Toshiba Corp | Mri apparatus |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| WO2006040155A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| CA2584833A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines |
| EP1961742A1 (en) | 2007-02-22 | 2008-08-27 | Novartis AG | compounds of formula (I) as serine protease inhibitors |
| WO2008127188A1 (en) | 2007-04-12 | 2008-10-23 | Allbay Ab | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
| WO2008133884A2 (en) * | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| ES2528040T3 (es) | 2007-06-18 | 2015-02-03 | A.Carlsson Research Ab | Uso de estabilizadores de dopamina |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| US20130216856A1 (en) | 2010-07-02 | 2013-08-22 | Marco Burtchen | Mechanical component and method of surface hardening |
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| JP6348283B2 (ja) * | 2011-01-27 | 2018-06-27 | ニューレン ファーマシューティカルズ リミテッド | グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療 |
| CA2847736A1 (en) | 2011-09-07 | 2013-03-14 | IVAX International GmbH | A new polymorphic form of pridopidine hydrochloride |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| IN2015DN03219A (pl) | 2012-09-27 | 2015-10-02 | Teva Pharma | |
| WO2014052935A2 (en) | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| SG11201509729YA (en) | 2013-06-21 | 2015-12-30 | Teva Pharmaceuticals Int Gmbh | Use of high dose pridopidine for treating huntington's disease |
| EA201691454A1 (ru) | 2014-01-22 | 2017-01-30 | Тева Фармасьютикалз Интернэшнл Гмбх | Композиции придопидина модифицированного высвобождения |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| MX378579B (es) | 2015-02-25 | 2025-03-11 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| US20200375966A1 (en) | 2016-09-15 | 2020-12-03 | Prilenia Therapeutics Development Ltd | Use of pridopidine for the treatment of anxiety and depression |
| HRP20260072T1 (hr) | 2019-06-12 | 2026-02-27 | Prilenia Neurotherapeutics Ltd. | Supstanca koja obuhvaća pridopidin i njegov analog za liječenje huntingtonove bolesti i njezinih simptoma |
-
2018
- 2018-01-18 PL PL18741607.8T patent/PL3570940T3/pl unknown
- 2018-01-18 HU HUE18741607A patent/HUE068300T2/hu unknown
- 2018-01-18 CN CN201880007913.2A patent/CN110505902B/zh active Active
- 2018-01-18 WO PCT/US2018/014169 patent/WO2018136600A1/en not_active Ceased
- 2018-01-18 EP EP18741607.8A patent/EP3570940B1/en active Active
- 2018-01-18 IL IL268125A patent/IL268125B2/en unknown
- 2018-01-18 AU AU2018210145A patent/AU2018210145B2/en active Active
- 2018-01-18 DK DK18741607.8T patent/DK3570940T3/da active
- 2018-01-18 CA CA3050700A patent/CA3050700C/en active Active
- 2018-01-18 ES ES18741607T patent/ES2972205T3/es active Active
- 2018-01-18 JP JP2019539958A patent/JP7114604B2/ja active Active
- 2018-01-18 BR BR112019015000-5A patent/BR112019015000A2/pt not_active Application Discontinuation
-
2019
- 2019-07-17 US US16/514,167 patent/US11234973B2/en active Active
-
2022
- 2022-01-31 US US17/588,403 patent/US12551474B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE068300T2 (hu) | 2024-12-28 |
| US20190336488A1 (en) | 2019-11-07 |
| JP7114604B2 (ja) | 2022-08-08 |
| CN110505902A (zh) | 2019-11-26 |
| AU2018210145B2 (en) | 2023-06-29 |
| EP3570940A1 (en) | 2019-11-27 |
| EP3570940A4 (en) | 2020-10-28 |
| US20220202798A1 (en) | 2022-06-30 |
| IL268125B2 (en) | 2023-04-01 |
| WO2018136600A1 (en) | 2018-07-26 |
| IL268125B (en) | 2022-12-01 |
| US12551474B2 (en) | 2026-02-17 |
| AU2018210145A1 (en) | 2019-08-29 |
| CN110505902B (zh) | 2022-11-11 |
| DK3570940T3 (da) | 2024-02-19 |
| CA3050700C (en) | 2023-10-03 |
| US11234973B2 (en) | 2022-02-01 |
| ES2972205T3 (es) | 2024-06-11 |
| IL268125A (en) | 2019-09-26 |
| BR112019015000A2 (pt) | 2020-04-07 |
| EP3570940B1 (en) | 2023-12-13 |
| JP2020514313A (ja) | 2020-05-21 |
| CA3050700A1 (en) | 2018-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273495A (en) | Treatment of fragile X syndrome with cannabidiol | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| PL3570940T3 (pl) | Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x | |
| IL258964A (en) | Thin and flexible absorbent items | |
| IL250016A0 (en) | Antisense oligonucleotides for the treatment of type 2 syndrome | |
| IL258962A (en) | Thin and flexible absorbent items | |
| GB2574762B (en) | Absorbent article | |
| GB201621480D0 (en) | Use of cannabinoids in the treatment of angelman syndrome | |
| IL258963A (en) | Thin and flexible absorbent items | |
| GB2574984B (en) | Thong-style absorbent article | |
| SG11202004898VA (en) | Underpants-shaped absorbent article | |
| GB2581054B (en) | Absorbent article | |
| GB2581058B (en) | Absorbent article | |
| SG11202000921XA (en) | Absorbent article | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| ZA202003100B (en) | Absorbent article component | |
| GB202017373D0 (en) | Absorbent article | |
| PL3716927T3 (pl) | Wyrób chłonny | |
| PL3691592T3 (pl) | Wyrób chłonny | |
| HUE066511T2 (hu) | Készítmények hunter-szindróma kezelésére | |
| GB2581084B (en) | Absorbent article | |
| SG11202000922VA (en) | Absorbent article | |
| CA186506S (en) | Absorbent article | |
| CA186507S (en) | Absorbent article | |
| CA186508S (en) | Absorbent article |